Amgen Hands Omecamtiv Back To Cytokinetics
Cytokinetics Assessing Commercializing On Its Own Or With New Partner
Amgen handed omecamtiv mecarbil back to Cytokinetics after data didn't meet a "high bar" in a Phase III heart failure trial • Source: Shutterstock 
